All In Biotech

Drug Trial Radar · NCT00630539

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II Dose Ranging, 12-Week, Randomized , Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 5 mg, 15 mg and 30 mg Daily Doses With Placebo

Last checked: Nov 20, 2026Latest source record: Jun 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Aug 2007

Primary completion

Jan 2008

Study completion Feb 2008

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
Collaborators
Hormos Medical; QuatRx Pharmaceuticals
First posted
Mar 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II.

Conditions

  • Atrophy
  • Vaginal Diseases

Interventions

  • PlaceboDrug

    1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

  • Ospemifene 5 mgDrug

    1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

  • Ospemifene 15 mgDrug

    1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

  • Ospemifene 30 mgDrug

    1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal SmearTime frame: 12 weeks
  2. Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of the Vaginal SmearTime frame: 12 weeks
  3. Mean Change From Baseline in Vaginal pHTime frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.